Arbutus Biopharma

ABUS

Arbutus Biopharma Corporation is a publicly traded (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.It is headquartered in Vancouver, British Columbia and has research facilities in Warminste …

Insider trades and stock quote 2024-2026

All insider trades at Arbutus Biopharma

Subscribe RSS
Date Type Insider Position Ø-Price Volume
2/4/2025 Sell Naftzger, J. Christopher General Counsel and CCO $3.3 $37,206
2/4/2025 Sell Mcelhaugh, Michael J. Interim President & CEO $3.3 $78,103
2/4/2025 Sell Sims, Karen Chief Medical Officer $3.3 $63,519
2/4/2025 Sell Hastings, David C. Chief Financial Officer $3.3 $72,827
All information without guarantee! No recommendation/consultation! © U.S. Securities and Exchange Commission (SEC)